Trial Profile
Safety and efficacy of nimotuzumab in combination with mitomycin, fluorouracil and radiation in immunocompetant patients with anal carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Mar 2015
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary) ; Fluorouracil; Mitomycin
- Indications Anal cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- 12 Mar 2015 New trial record